Previous Close | 1.1500 |
Open | 1.1500 |
Bid | 0.9000 |
Ask | 1.1500 |
Strike | 15.00 |
Expire Date | 2024-12-20 |
Day's Range | 1.1500 - 1.1500 |
Contract Range | N/A |
Volume | |
Open Interest | 352 |
SAN DIEGO, September 26, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 23, 2024, the Board of Directors granted Catherine Owen Adams, Acadia’s new Chief Executive Officer, a one-time sign-on equity award of (i) 353,261 options to purchase shares of Acadia’s common stock with an exercise price of $16.29 per share, Acadia’s closing trading price on September 23, 2024, which vest 25% on the first anniversary of grant and in equal monthly installments over the th
SAN DIEGO, September 23, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors.
The market has stayed flat over the past 7 days but has risen 23% in the past 12 months, with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these trends is crucial for investors looking to maximize their returns.